Drug intelligence / Profile preview

IN-B009

Development stage: Phase 1
Lead developer: HK inno.N Corporation
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IN-B009 is a vaccine candidate being developed by HK inno.N for the prevention of COVID-19. It is administered via intramuscular injection and is currently in Phase 1 clinical trials for this indication. The mechanism of action is as a vaccine, stimulating an immune response to protect against SARS-CoV-2 infection. As of now, it has not received regulatory approval in any country and no brand or trade names are associated with it[1].

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on IN-B009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-B009.

Explore the full profile